14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
MLAB vs PLUS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PLUS Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–3 Matrix Metrics)
PLUS Overall Winner
6-Pillar Tally: MLAB 3 – 3 PLUS
Matrix Metrics: MLAB 3 – 6 PLUS
As of Nov 19, 2026, ePlus Inc (PLUS) is the stronger overall head-to-head candidate over Mesa Laboratories Inc (MLAB) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). MLAB carries a Unified Composite Score of 43.8/100 (HOLD) at $133.41 (24.8x Forward P/E, 10.4% operating margin), whereas PLUS carries 40.6/100 (SELL) at $95.64 (17.2x Forward P/E, 6.8% operating margin).
Composite vs. Pillar Nuance: While MLAB currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. PLUS 40.6/100 SELL), PLUS captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (6.8% vs. 10.4% operating margin) and revenue trajectory (+9.7% vs. +2.6% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLAB vs PLUS. Trailing 12-month operating profitability (MLAB 10.4% vs PLUS 6.8%) and valuation multiples (MLAB 24.8x vs PLUS 17.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Scientific & Technical Instruments value chain with $774.6M market capitalization and 10.4% operating margin.
OpEx & R&D Reinvestment54.4% of Rev ($137M)
90D Engineering Disclosures0 Published
PLUS Moat ProfileCyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $2.5B market capitalization and 6.8% operating margin.
OpEx & R&D Reinvestment18.4% of Rev ($461M)
90D Engineering Disclosures0 Published
Investor FAQ MLAB vs PLUS Key Questions & Quantitative Answers
As of Nov 19, 2026, ePlus Inc (PLUS) is the stronger overall head-to-head candidate over Mesa Laboratories Inc (MLAB) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). MLAB carries a Unified Composite Score of 43.8/100 (HOLD) at $133.41 (24.8x Forward P/E, 10.4% operating margin), whereas PLUS carries 40.6/100 (SELL) at $95.64 (17.2x Forward P/E, 6.8% operating margin). Composite vs. Pillar Nuance: While MLAB currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. PLUS 40.6/100 SELL), PLUS captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (6.8% vs. 10.4% operating margin) and revenue trajectory (+9.7% vs. +2.6% YoY).
PLUS leads the Growth & Scale pillar: MLAB posts +2.6% YoY revenue growth and +67.0% YoY earnings growth on $251M TTM revenue (64.8% gross margin, 10.4% operating margin), compared with PLUS at +9.7% YoY revenue growth and +18.0% YoY earnings growth on $2.51B TTM revenue (25.2% gross margin, 6.8% operating margin). On trailing 12-month operating scale, MLAB generates $251M in USD-normalized revenue versus $2.51B for PLUS. In operating R&D and SG&A reinvestment, MLAB deploys 54.4% of Rev ($137M) (0 90-day corporate R&D disclosures) versus 18.4% of Rev ($461M) (0 disclosures) for PLUS.
PLUS screens cheaper on headline valuation multiples. MLAB trades at 24.8x Forward P/E, 118.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (19.4% EBITDA margin), whereas PLUS trades at 17.2x Forward P/E, 20.3x Trailing P/E, 1.11x PEG, and 0.9x EV/Revenue (1.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MLAB (3.6% ROE) versus PLUS (11.6% ROE) capital efficiency.
In options market volatility and institutional positioning, MLAB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.12β · 53% Vol realized risk). By comparison, PLUS carries 56.1% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.53x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.87β · 57% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.